Filing identity and business context
The supplied filing is NorthView Acquisition Corp.’s Form 10-Q for the quarter ended June 30, 2022, filed August 11, 2022. It is not a Profusa, Inc. filing, despite the request metadata naming Profusa. NorthView is a blank-check company seeking a business combination, with a stated focus on healthcare innovation; it had not selected a target or begun operating activities.
Financial results and liquidity
| Metric | Three months ended June 30, 2022 | Six months ended June 30, 2022 |
|---|---|---|
| Operating revenue | None | None |
| Formation and operating costs | $217,525 | $459,121 |
| Trust interest income | $161,816 | $234,500 |
| Gain from warrant-liability remeasurement | $1,294,594 | $5,172,523 |
| Net income | $1,212,363 | $4,921,380 |
| Net income per share | $0.05 | $0.20 |
Reported profit was driven primarily by noncash gains from the decline in the fair value of warrant liabilities, rather than business revenue. No operating margin is meaningful because the company had no operating revenue.
- At June 30, 2022, cash outside the trust was $480,726; working capital was approximately $0.8 million.
- Trust assets totaled $191.9 million. The trust held U.S. Treasury bills and money-market funds; reported six-month interest income was $234,500.
- Operating cash use was $293,986 for the six months. Cash declined from $741,228 at December 31, 2021 to $480,726.
- Total liabilities were $2.2 million, including $2.0 million of warrant liabilities. The filing reports no long-term debt, lease obligations, or outstanding working-capital loans.
- Public shares classified as subject to possible redemption totaled $191.8 million. Stockholders’ deficit was $1.1 million.
Changes and comparison
For the six months, net income was $4.9 million versus a $338 loss from inception through June 30, 2021; the periods are not comparable because the company was formed in April 2021 and completed its IPO in December 2021. Compared with December 31, 2021, warrant liabilities fell from $7.2 million to $2.0 million, producing a substantial reported gain. Cash decreased by $260,502, while trust assets increased modestly. The filing does not provide a comparable second-quarter 2021 operating period.
Outlook, risks, and unusual items
- NorthView had until March 22, 2023 to complete a business combination, with the possibility of up to two three-month extensions subject to sponsor deposits into the trust. Management said completion by the deadline was uncertain.
- If no transaction is completed by the deadline, the company must liquidate and redeem public shares. Management concluded this possibility raises substantial doubt about the company’s ability to continue as a going concern for the next 12 months.
- The company had no identified target. It expects to incur additional public-company, due-diligence, and transaction costs; completion of a transaction or additional financing is not assured.
- A business-combination marketing fee of $6,986,250, equal to 3.68% of IPO gross proceeds, is payable to advisors upon a completed transaction. The sponsor may, but is not required to, provide working-capital or extension loans.
- Management said COVID-19 and the Russia-Ukraine war could adversely affect the company’s finances or target search, but the specific impact was not determinable.
- The company reported effective disclosure controls as of June 30, 2022, no material changes in internal control, and no material changes to previously disclosed risk factors.
Important facts for investors to verify
- Confirm the issuer: this document is for NorthView Acquisition Corp., not Profusa, Inc.
- Check whether NorthView identified or completed a business combination, and whether it sought an extension, by the March 22, 2023 deadline.
- Assess the company’s remaining cash outside the trust and its ability to fund transaction costs; sponsor financing is discretionary.
- Distinguish operating performance from reported earnings, which were substantially affected by warrant fair-value changes.
- Review redemption terms, trust-account balances, warrant dilution and liabilities, and transaction-related fees in any proposed combination.